All In Biotech

Drug Trial Radar · NCT03114982

The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age

Randomized, Double-blinded, Parallel-group, Exploratory Study to Assess The Immunogenicity and Safety of NBP608 and Varivax in Healthy Children

Last checked: Nov 19, 2026Latest source record: Apr 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

May 2016

Primary completion

Jul 2016

Study completion Nov 2016

Sponsor

Lead sponsor
SK Chemicals Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 months, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates the immunogenicity and safety of three different potencies of NBP608 and Varivax which are indicated for active immunization for the prevention of varicella. Total of 152 subjects (38 subjects per each treatment arm) of 12 months to 12 years of age are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.

Conditions

  • Varicella

Interventions

  • NBP608Biological

    Preparation of the Oka/SK strain of live, attenuated varicella virus

  • VarivaxBiological

    Preparation of the Oka/Merck strain of live, attenuated varicella virus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate measured by FAMA(Fluorescent Antibody to Membrane Antigen) assayTime frame: 6 weeks after IP(Investigational Product) vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Insitute for Torpical Medicine

    Muntinlupa City, National Capital Region, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.